Prashant Joshi

1.7k total citations
61 papers, 1.4k citations indexed

About

Prashant Joshi is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Prashant Joshi has authored 61 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 15 papers in Pharmacology and 15 papers in Oncology. Recurrent topics in Prashant Joshi's work include Antibiotic Resistance in Bacteria (12 papers), Multiple Myeloma Research and Treatments (8 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Prashant Joshi is often cited by papers focused on Antibiotic Resistance in Bacteria (12 papers), Multiple Myeloma Research and Treatments (8 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Prashant Joshi collaborates with scholars based in India, United States and United Kingdom. Prashant Joshi's co-authors include Sandip B. Bharate, Ram A. Vishwakarma, Bhabatosh Chaudhuri, Ajay Kumar, Sonali S. Bharate, Sudhakar Manda, Vinay R. Sonawane, Shashi Bhushan, Mahesh Patel and Abubakar Wani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Prashant Joshi

59 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Prashant Joshi India	24	620	370	313	249	239	61	1.4k
Mаhmoud Youns Egypt	27	1.0k 1.7×	610 1.6×	233 0.7×	89 0.4×	195 0.8×	49	2.3k
Amit Nargotra India	22	641 1.0×	326 0.9×	215 0.7×	175 0.7×	81 0.3×	54	1.2k
Amit Choudhari India	14	558 0.9×	345 0.9×	165 0.5×	94 0.4×	116 0.5×	25	1.4k
Moataz A. Shaldam Egypt	24	827 1.3×	564 1.5×	146 0.5×	160 0.6×	154 0.6×	75	1.5k
K. Venkateswara Swamy India	21	533 0.9×	293 0.8×	107 0.3×	217 0.9×	152 0.6×	57	1.3k
Kuang‐Chi Lai Taiwan	33	1.5k 2.3×	216 0.6×	393 1.3×	284 1.1×	373 1.6×	70	2.8k
Rajesh N. Gacche India	29	987 1.6×	867 2.3×	305 1.0×	66 0.3×	324 1.4×	105	2.7k
Fardous F. El‐Senduny Egypt	20	462 0.7×	473 1.3×	170 0.5×	168 0.7×	137 0.6×	58	1.4k
Onat Kadioglu Germany	26	1.1k 1.7×	175 0.5×	198 0.6×	77 0.3×	486 2.0×	63	2.0k
Bethsebie Lalduhsaki Sailo India	14	774 1.2×	151 0.4×	238 0.8×	203 0.8×	182 0.8×	20	1.6k

Countries citing papers authored by Prashant Joshi

Since Specialization

Citations

This map shows the geographic impact of Prashant Joshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prashant Joshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prashant Joshi more than expected).

Fields of papers citing papers by Prashant Joshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prashant Joshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prashant Joshi. The network helps show where Prashant Joshi may publish in the future.

Co-authorship network of co-authors of Prashant Joshi

This figure shows the co-authorship network connecting the top 25 collaborators of Prashant Joshi. A scholar is included among the top collaborators of Prashant Joshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prashant Joshi. Prashant Joshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ailawadhi, Sikander, Hans C. Lee, James Omel, et al.. (2024). Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry. Blood Cancer Journal. 14(1). 198–198. 2 indexed citations

Joshi, Prashant, et al.. (2024). Sub-minimum inhibitory concentrations in ceftazidime exacerbate the formation of Acinetobacter baumannii biofilms. Microbial Pathogenesis. 199. 107229–107229. 2 indexed citations

Hujer, Andrea M., Steven H. Marshall, Andrew R Mack, et al.. (2023). Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam. mBio. 14(6). e0111823–e0111823. 11 indexed citations

Babbar, Shashi B., Shally Awasthi, Sangeeta Pandey, et al.. (2023). ANTIBIOTICS AND SURFACE DISINFECTANT INDUCE VBNC AND EMERGENCE OF RESISTANCE IN HOSPITAL-ASSOCIATED PATHOGENS. International Journal of Infectious Diseases. 130. S98–S98. 1 indexed citations

Lee, Hans C., Karthik Ramasamy, Katja Weisel, et al.. (2022). Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. Clinical Lymphoma Myeloma & Leukemia. 23(2). 112–122. 6 indexed citations

Barceló, Isabel M., Gabriel Cabot, Prashant Joshi, et al.. (2021). In vitroevolution of cefepime/zidebactam (WCK 5222) resistance inPseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact onin vivoefficacy. Journal of Antimicrobial Chemotherapy. 76(10). 2546–2557. 23 indexed citations

Joshi, Prashant, Rahul Shrivastava, Sachin Bhagwat, & Mahesh Patel. (2021). Activity of β-lactam plus β-lactam-enhancer combination cefepime/zidebactam against Klebsiella pneumoniae harbouring defective OmpK35/36 porins and carbapenemases. Diagnostic Microbiology and Infectious Disease. 101(2). 115481–115481. 7 indexed citations

Ailawadhi, Sikander, Kathleen Toomey, James W. Hardin, et al.. (2020). Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.. Journal of Clinical Oncology. 38(15_suppl). 8518–8518. 2 indexed citations

Moyá, Bartolomé, Isabel M. Barceló, Gabriel Cabot, et al.. (2019). In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 63(5). 40 indexed citations

10.

Ruparelia, Ketan C., Vinay R. Sonawane, Prashant Joshi, et al.. (2017). Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines. European Journal of Medicinal Chemistry. 129. 159–174. 48 indexed citations

11.

Joshi, Prashant, Mohit Sharma, Naresh K. Satti, et al.. (2017). Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance. Bioorganic & Medicinal Chemistry Letters. 27(16). 3683–3687. 53 indexed citations

12.

Siddique, Mohd Usman Mohd, Vinay R. Sonawane, Prashant Joshi, et al.. (2017). Quinazoline derivatives as selective CYP1B1 inhibitors. European Journal of Medicinal Chemistry. 130. 320–327. 47 indexed citations

13.

Joshi, Prashant, et al.. (2017). (E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent. Bioorganic & Medicinal Chemistry Letters. 27(24). 5409–5414. 14 indexed citations

14.

Singh, Samsher, Nitin Pal Kalia, Prashant Joshi, et al.. (2017). Boeravinone B, A Novel Dual Inhibitor of NorA Bacterial Efflux Pump of Staphylococcus aureus and Human P-Glycoprotein, Reduces the Biofilm Formation and Intracellular Invasion of Bacteria. Frontiers in Microbiology. 8. 1868–1868. 72 indexed citations

15.

Kumar, Vikas, Santosh Kumar Guru, Shreyans K. Jain, et al.. (2016). A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties. Bioorganic & Medicinal Chemistry Letters. 26(15). 3457–3463. 35 indexed citations

16.

Yadav, Rammohan R., Santosh Kumar Guru, Prashant Joshi, et al.. (2016). 6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors. European Journal of Medicinal Chemistry. 122. 731–743. 42 indexed citations

17.

Manda, Sudhakar, Sadhana Sharma, Abubakar Wani, et al.. (2015). Discovery of a marine-derived bis-indole alkaloid fascaplysin, as a new class of potent P-glycoprotein inducer and establishment of its structure–activity relationship. European Journal of Medicinal Chemistry. 107. 1–11. 63 indexed citations

18.

Bharate, Sandip B., Sudhakar Manda, Prashant Joshi, et al.. (2015). Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization. Cell Death and Disease. 6(5). e1743–e1743. 37 indexed citations

19.

Singh, Baljinder, Tabasum Sidiq, Prashant Joshi, et al.. (2013). Anti-inflammatory and immunomodulatory flavones fromActinocarya tibeticaBenth.. Natural Product Research. 27(23). 2227–2230. 12 indexed citations

20.

Schmidt, Carl, Martha J. Shrubsole, Dean Billheimer, et al.. (2006). Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia. Clinical Gastroenterology and Hepatology. 4(11). 1358–1365. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact